ENVALITH
日本システム技術株式会社 logo

Japan System Techniques Co., Ltd.

4323・Prime Market・Information & Communication

Official website
日本システム技術株式会社 logo
Japan System Techniques Co., Ltd.4323

Business

Japan System Techniques Co., Ltd. (JAST) is a fully independent IT services company founded in 1973. The group consists of 16 companies, including 15 consolidated subsidiaries, and operates four businesses: (1) DX & SI Business (system development for the financial, telecommunications, and manufacturing industries), (2) Package Business (proprietary brand products including the "GAKUEN Series" for universities and "BankNeo" for financial institutions), (3) Medical Big Data Business (medical claim (receipt) auditing and insurer operations support), and (4) Global Business (ERP/HRM solutions for ASEAN and the Middle East). Its greatest distinguishing feature is that it maintains an independent position unaffiliated with any corporate group, allowing it to serve a wide range of customers regardless of industry, technology field, or platform. Consolidated net sales for FY2026 (ending March 2026) were ¥32,459 million.

Business Model

In the DX & SI Business, the company builds up revenue primarily through contracted development and prime contractor projects, while promoting a shift toward an offering-type business model. In the Package Business, in addition to product sales, maintenance, and implementation support for the GAKUEN Series and BankNeo, the company is securing stable revenue through a transition to subscription-based services. In the Medical Big Data Business, the company provides receipt (medical claim) auditing, data utilization, and BPO as a one-stop service, building a recurring-revenue-based earnings foundation. The company is also pursuing a cross-sell strategy that leverages the customer base, human resources, and brand assets of each business across the group.

Company Strengths

The company has maintained a completely independent position, unaffiliated with any corporate group, since its founding, serving diverse industries including finance, telecommunications, manufacturing, public sector, education, and healthcare. In FY2026 (ending March 2026), it recorded transactions with major companies such as NTT DOCOMO Solutions (¥3,983 million, 12.3% of sales) and TIS (¥1,636 million, 5.0% of sales), building a diversified customer base without dependence on any specific parent company.

The Package Business achieved a high operating margin of 33.3% in FY2026 (ending March 2026) (operating profit of ¥2,293 million). The GAKUEN Series for universities has a track record of over 30 years since its launch in 1994, and together with BankNeo for financial institutions, generates ongoing revenue from maintenance and implementation support. The transition to a subscription-based model is also underway, which is expected to enhance long-term customer lifetime value (LTV).

As of the end of FY2026 (ending March 2026), the equity ratio stood at 66.2% (a continued improvement from 58.9% in FY2022 (ending March 2022)), with zero interest-bearing debt and a cash flow to interest-bearing debt ratio of 0.0 years. Operating cash flow amounted to ¥3,028 million, while ROE was 16.6% and ROIC was 18.0%, both maintaining levels well above the cost of capital.

ENVALITH's Perspective

In FY2026 (ending March 2026), Package Business operating profit reached ¥2,293 million (up 46.6% year-on-year), a standout increase, with the operating margin reaching 33.3%. This was mainly driven by increased sales and implementation support services for the GAKUEN Series procurement/sales business and increased PP sales of BankNeo. While there is an external tailwind from expanding DX investment by universities, the improvement in profitability was primarily driven by the competitiveness of the company's own products and the depth of its customer base, and this deserves structural recognition for driving the improvement in the company-wide operating margin to 12.0% (from 10.9% in the previous period).

The Global Business saw a rapid deterioration in profitability in FY2026 (ending March 2026), with net sales of ¥2,254 million (down 18.1% year-on-year) and an operating loss of ¥400 million (a significant deterioration from a loss of ¥61 million in the previous period). An impairment loss of ¥296 million was recognized at the Malaysian and Chinese subsidiaries, writing down the book value of goodwill, customer-related assets, and fixed assets to a memorandum value. While external factors such as geopolitical risk and declining SAP order intake in local markets are the main causes, the turnaround scenario for the business remains unclear, and clarification of its positioning within the medium-term management plan is required.

The company's forecast for FY2027 (ending March 2027) calls for net sales of ¥34,300 million (up 5.7% year-on-year) and operating profit of ¥4,150 million (up 6.1% year-on-year), a significant deceleration from the FY2026 (ending March 2026) growth rates of 10.7% in sales and 22.7% in operating profit. This appears to be a conservative assumption that factors in continued losses in the Global Business, and there is room for upside if the three businesses of DX & SI Business, Package Business, and Medical Big Data Business continue to perform well. On the other hand, attention should be paid to the risk that rising personnel expenses and outsourcing costs, an external factor, could cap upside in the profit margin.

Growth Strategy

In the medium-term management plan for FY2026–FY2028 (ending March 2026 to March 2028), the company positions education and healthcare as core areas, aiming for VISION 2035 (revenue of ¥100 billion)

The company is shifting from a region-based SI structure to an industry- and solution-based business structure, moving from contract development-centric operations toward an offering-type business that systematizes operational know-how and development assets. It aims to enhance profitability and achieve sustainable growth by providing highly reproducible and scalable services. In FY2026 (ending March 2026), strong performance in large-scale prime contracts drove revenue of ¥19,806 million (up 12.9% year on year).

The company is strengthening its competitive advantage through R&D investment and the use of generative AI in the GAKUEN Series, BankNeo, and JMICS. It aims to expand market share and increase LTV by expanding its service lineup leveraging its existing customer base. In FY2026 (ending March 2026), operating profit in the Package Business already achieved a strong result of ¥2,293 million (up 46.6% year on year).

In addition to revenue growth in claims review, data utilization, and cloud services for public assistance recipients, the company is promoting comprehensive medical DX services leveraging improved profitability at Casesheep. It is also considering entry into new markets through academic partnerships, M&A, and alliances. In FY2026 (ending March 2026), revenue reached ¥3,503 million (up 11.2% year on year) and operating profit ¥887 million (up 33.9% year on year), continuing high growth.

Due to the deteriorating business environment at the Malaysian and Chinese subsidiaries, the company recorded an impairment loss of ¥296 million. While it aims to diversify revenue through expanded support for ERP product implementation beyond SAP and through the use of alliances, in FY2026 (ending March 2026) the operating loss widened to ¥400 million. The business is at a stage where its positioning is being reviewed as part of the business portfolio restructuring under the medium-term management plan.

The company treats establishing an ROE level of 20% as a key management indicator, aiming to balance growth investment with shareholder returns. The annual dividend for FY2026 (ending March 2026) is ¥45 (a significant increase from ¥27 in the previous fiscal year), with a payout ratio of 42.4%. The forecast dividend for FY2027 (ending March 2028) is ¥50 (payout ratio of 41.9%), planning a further dividend increase. The company intends to continue management with awareness of its cost of capital.

Last updated: July 19, 2026